Trial Profile
An Open-label, 2 Replicate Single Dose Euglycemic Glucose-Clamp Trial to Characterize PK and PD Within-Subject Variability of a Single Dose of Afrezza Inhaled Technosphere Insulin in Patients With Diabetes Mellitus Type 1 (T1DM)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Insulin (Primary)
- Indications Type 1 diabetes mellitus
- Focus Pharmacodynamics; Pharmacokinetics
- Sponsors Sanofi
- 27 Nov 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 07 Jul 2015 Status changed from not yet recruiting to recruiting as per ClinicalTrials.gov record.
- 02 Jul 2015 New trial record